Evidence for Andexanet Alpha in Reversing Intracerebral Hemorrhage due to Factor Xa Inhibitors?
Date
2021-05-10Journal
StrokePublisher
Lippincott Williams and WilkinsType
Article
Metadata
Show full item recordIdentifier to cite or link to this item
http://hdl.handle.net/10713/15931ae974a485f413a2113503eed53cd6c53
10.1161/STROKEAHA.120.031825
Scopus Count
Collections
Related articles
- Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
- Authors: Maragkos GA, Nelton EB, Richter S, Stippler M
- Issue date: 2020 Oct
- Andexanet Alfa for Factor Xa Inhibitor-Associated Intracerebral Hemorrhage: Does a Specific Reversal Agent Justify Its Cost?
- Authors: Patel N, Morris NA
- Issue date: 2021 Nov 23
- An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
- Authors: Giovino A, Shomo E, Busey KV, Case D, Brockhurst A, Concha M
- Issue date: 2020 Aug
- Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence.
- Authors: Abdulrehman J, Eikelboom JW, Siegal DM
- Issue date: 2019 Nov
- Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
- Authors: Escolar G, Diaz-Ricart M, Arellano-Rodrigo E
- Issue date: 2017 May